A large number of new therapeutic agents have been studied for patients with relapsed/refractory follicular lymphoma (FL). Among new therapies, idelalisib, a novel PI3K inhibitor, shows promising results in the management of this disease.

Marangon, M., Pellegrini, C., Argnani, L., Zinzani, P.L. (2017). Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report. TUMORI, 103(Suppl. 1), 41-43 [10.5301/tj.5000679].

Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report

Marangon, Miriam;Pellegrini, Cinzia;Argnani, Lisa;Zinzani, Pier Luigi
2017

Abstract

A large number of new therapeutic agents have been studied for patients with relapsed/refractory follicular lymphoma (FL). Among new therapies, idelalisib, a novel PI3K inhibitor, shows promising results in the management of this disease.
2017
Marangon, M., Pellegrini, C., Argnani, L., Zinzani, P.L. (2017). Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report. TUMORI, 103(Suppl. 1), 41-43 [10.5301/tj.5000679].
Marangon, Miriam; Pellegrini, Cinzia; Argnani, Lisa; Zinzani, Pier Luigi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/615031
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact